查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538352

创伤后头痛市场报告：2030 年趋势、预测与竞争分析

Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

外伤后头痛的趋势与预测

预计 2024 年至 2030 年，全球创伤后头痛 (PTH) 市场将以 4.3% 的复合年增长率成长。该市场的主要驱动因素是创伤性脑损伤盛行率的上升、新治疗方案的创造以及对 PTH 认识的提高。全球创伤后头痛市场的未来看起来充满希望，医院药局、零售药局和线上药局市场充满机会。

按部位分類的外伤后头痛

该研究包括按药物类型、分销管道、给药途径和地区分類的全球创伤后头痛市场预测。

创伤后头痛市场洞察

Lucintel 预测，偏头痛专用已停产曲坦类药物预计将在预测期内强劲成长。

在这个市场中，线上药局预计将呈现更高的成长。

预计北美在预测期内将经历最高的成长。

常问问题

Q1.市场成长预测是多少：

A1. 2024 年至 2030 年，全球创伤后头痛市场预计将以 4.3% 的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动力是创伤性脑损伤盛行率的上升、新治疗方案的创造以及人们对 PTH 的认识不断提高。

Q3.市场的主要细分市场是：

A3. 创伤后头痛市场前景广阔，医院药局、零售药局和线上药局市场充满机会。

Q4.市场的主要企业是：

A4.与相关企业如下：

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计口服製剂在预测期内将经历最高增长。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 预计北美地区在预测期内将出现最高成长。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球创伤后头痛市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球创伤后头痛市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类型分類的全球创伤后头痛市场
    • 发炎药
    • 乙酰水杨酸
    • 乙酰胺酚
    • 偏头痛特异性停药曲坦类药物
  • 按分销管道分類的全球创伤后头痛市场
    • 医院药房
    • 零售药房
    • 网路药房
  • 按途径的全球创伤后头痛市场
    • 口服剂
    • 注射

第四章 2018-2030年区域市场趋势及预测分析

  • 全球创伤后头痛市场（按地区）
  • 北美创伤后头痛市场
  • 欧洲创伤后头痛市场
  • 亚太创伤后头痛市场
  • 其他地区外伤后头痛市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类型分類的全球创伤后头痛市场成长机会
    • 全球创伤后头痛市场成长机会（按分销管道）
    • 途径的全球创伤后头痛市场成长机会
    • 全球创伤后头痛市场成长机会（按地区）
  • 全球创伤后头痛市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球创伤后头痛市场产能扩张
    • 全球创伤后头痛市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals
简介目录

Post-Traumatic Headache Trends and Forecast

The future of the global post-traumatic headache market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets. The global post-traumatic headache market is expected to grow with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are rising prevalence of traumatic brain injuries, creation of novel treatment alternatives, and increasing recognition of PTH.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Post-Traumatic Headache by Segment

The study includes a forecast for the global post-traumatic headache by drug type, distribution channel, route of administration, and region.

Post-Traumatic Headache Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Anti-Inflammatory Drug
  • Acetylsalicylic Acid
  • Acetaminophen
  • Migraine-Specific Abortant Triptan

Post-Traumatic Headache Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Post-Traumatic Headache Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Injectable

Post-Traumatic Headache Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Post-Traumatic Headache Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post-traumatic headache companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post-traumatic headache companies profiled in this report include-

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Post-Traumatic Headache Market Insights

Lucintel forecasts that migraine-specific abortant triptan is expected to witness higher growth over the forecast period.

Within this market, online pharmacies is expected to witness the higher growth.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Post-Traumatic Headache Market

Market Size Estimates: Post-traumatic headache market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Post-traumatic headache market size by drug type, distribution channel, route of administration, and region in terms of value ($B).

Regional Analysis: Post-traumatic headache market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, route of administration, and regions for the post-traumatic headache market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post-traumatic headache market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for post-traumatic headache market?

Answer: The global post-traumatic headache market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the post-traumatic headache market?

Answer: The major drivers for this market are rising prevalence of traumatic brain injuries, creation of novel treatment alternatives and increasing recognition of PTH.

Q3. What are the major segments for post-traumatic headache market?

Answer: The future of the post-traumatic headache market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets.

Q4. Who are the key post-traumatic headache market companies?

Answer: Some of the key post-traumatic headache companies are as follows:

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Q5. Which post-traumatic headache market segment will be the largest in future?

Answer: Lucintel forecasts that oral is expected to witness the highest growth over the forecast period.

Q6. In post-traumatic headache market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the post-traumatic headache market by drug type (anti-inflammatory drug, acetylsalicylic acid, acetaminophen, and migraine-specific abortant triptan), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), route of administration (oral and injectable), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post-Traumatic Headache Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Post-Traumatic Headache Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Post-Traumatic Headache Market by Drug Type
    • 3.3.1: Anti-Inflammatory Drug
    • 3.3.2: Acetylsalicylic Acid
    • 3.3.3: Acetaminophen
    • 3.3.4: Migraine-Specific Abortant Triptan
  • 3.4: Global Post-Traumatic Headache Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Online Pharmacies
  • 3.5: Global Post-Traumatic Headache Market by Route of Administration
    • 3.5.1: Oral
    • 3.5.2: Injectable

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Post-Traumatic Headache Market by Region
  • 4.2: North American Post-Traumatic Headache Market
    • 4.2.1: North American Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.2.2: North American Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Post-Traumatic Headache Market
    • 4.3.1: European Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.3.2: European Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Post-Traumatic Headache Market
    • 4.4.1: APAC Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.4.2: APAC Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Post-Traumatic Headache Market
    • 4.5.1: ROW Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.5.2: ROW Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Post-Traumatic Headache Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Post-Traumatic Headache Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Post-Traumatic Headache Market by Route of Administration
    • 6.1.4: Growth Opportunities for the Global Post-Traumatic Headache Market by Region
  • 6.2: Emerging Trends in the Global Post-Traumatic Headache Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Post-Traumatic Headache Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post-Traumatic Headache Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Johnson & Johnson Health Care Systems
  • 7.3: Impax Laboratories
  • 7.4: AstraZeneca
  • 7.5: Grunenthal
  • 7.6: GlaxoSmithKline
  • 7.7: Glenmark Pharmaceutical
  • 7.8: Pfizer
  • 7.9: Merck & Co
  • 7.10: Aralez Pharmaceuticals